India, July 30 -- EyePoint Inc. (EYPT), a clinical-stage biopharmaceutical company, announced on Thursday the completion of enrolment in two Phase 3 COMO and CAPRI trials for DURAVYU in treating diabetic macular edema.
Diabetic macular edema (DME) is a form of gradual vision loss in patients of type 1 and type 2 diabetes, caused by blood vessels leaking into the macula. As the macula is responsible for focusing sharp images on the retina, the condition leads to blurred vision, severe vision loss, or even legal blindness. The disease affects about 28 million people worldwide.
DURAVYU is an intravitreal insert that allows for the sustained release of the tyrosine kinase inhibitor (TKI) vorolanib. This placed in the macula alongside Durasert...